{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T08:16:25Z","timestamp":1657095385274},"reference-count":27,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"DOI":"10.25259\/nmji_739_21","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T07:54:24Z","timestamp":1657094064000},"page":"376-378","update-policy":"http:\/\/dx.doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal gammopathy of unknown significance: Implications of Indian baseline data"],"prefix":"10.25259","volume":"34","author":[{"given":"Kaveri","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suvir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"10.25259\/NMJI_739_21\/ref-1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.25259\/NMJI_739_21\/ref-2","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: Aprospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.25259\/NMJI_739_21\/ref-3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_739_21\/ref-4","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.25259\/NMJI_739_21\/ref-5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.25259\/NMJI_739_21\/ref-6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"38","author":"Van De Donk","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.25259\/NMJI_739_21\/ref-7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"10.25259\/NMJI_739_21\/ref-8","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1182\/blood.V94.8.2583.420a05_2583_2589","article-title":"Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"94","author":"Avet-Loiseau","year":"1999","journal-title":"Blood"},{"key":"10.25259\/NMJI_739_21\/ref-9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"10.25259\/NMJI_739_21\/ref-10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","article-title":"Serial exome analysis of disease progression in premalignant gammopathies","volume":"28","author":"Zhao","year":"2014","journal-title":"Leukemia"},{"key":"10.25259\/NMJI_739_21\/ref-11","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.clml.2016.02.025","article-title":"Clonal evolution in multiple myeloma","author":"Fakhri","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.25259\/NMJI_739_21\/ref-12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the Global Burden of Disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.25259\/NMJI_739_21\/ref-13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0971-5851.123712","article-title":"Report of chronic myeloid leukemia in chronic phase from All India Institute of Medical Sciences, 1990\u20132010","volume":"34","author":"Mishra","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.25259\/NMJI_739_21\/ref-14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1385\/MO:19:3:141","article-title":"Lympho-hemopoietic malignancies in India","volume":"19","author":"Bhutani","year":"2002","journal-title":"Med Oncol"},{"key":"10.25259\/NMJI_739_21\/ref-15","first-page":"108","article-title":"A twelve year study of multiple myeloma at the All India Institute of Medical Sciences, New Delhi, India","volume":"16","author":"Gupta","year":"1995","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.25259\/NMJI_739_21\/ref-16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9343(98)00080-1","article-title":"Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly","volume":"104","author":"Cohen","year":"1998","journal-title":"Am J Med"},{"key":"10.25259\/NMJI_739_21\/ref-17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: A systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clinic Proc"},{"key":"10.25259\/NMJI_739_21\/ref-18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/leu.2011.368","article-title":"Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites","volume":"26","author":"Greenberg","year":"2012","journal-title":"Leukemia"},{"key":"10.25259\/NMJI_739_21\/ref-19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"key":"10.25259\/NMJI_739_21\/ref-20","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.clml.2018.06.005","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in India\u2013\u2013A hospital-based study","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.25259\/NMJI_739_21\/ref-21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_739_21\/ref-22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"key":"10.25259\/NMJI_739_21\/ref-23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Hematologica"},{"key":"10.25259\/NMJI_739_21\/ref-24","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.3390\/ijms19113621","article-title":"Prevention is the best treatment: The case for understanding the transition from monoclonal gammopathy of undetermined significance to myeloma","volume":"19","author":"Tomasson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.25259\/NMJI_739_21\/ref-25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas\u2014current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.25259\/NMJI_739_21\/ref-26","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: Apopulation-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"key":"10.25259\/NMJI_739_21\/ref-27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.17.00131","article-title":"Computational model of progression to multiple myeloma identifies optimum screening strategies","volume":"2","author":"Altrock","year":"2018","journal-title":"JCO Clin Cancer Inform"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/monoclonal-gammopathy-of-unknown-significance-implications-of-indian-baseline-data\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/monoclonal-gammopathy-of-unknown-significance-implications-of-indian-baseline-data\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T07:54:42Z","timestamp":1657094082000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/monoclonal-gammopathy-of-unknown-significance-implications-of-indian-baseline-data\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":27,"alternative-id":["10.25259\/NMJI_739_21"],"URL":"https:\/\/doi.org\/10.25259\/nmji_739_21","relation":{},"ISSN":["0970-258X"],"issn-type":[{"value":"0970-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"article-number":"376"}}